

An international multi-centre trial of tamoxifen versus anastrozole in postmenopausal women who have had a recent hormone receptor positive Ductal Carcinoma In Situ (DCIS)

| | | |
|--|---|---|
| Submission date 07/01/2005 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 26/04/2005 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 24/04/2025 | Condition category Cancer | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-tamoxifen-or-anastrozole-in-postmenopausal-women-with-ductal-carcinoma-in-situ-of-the-breast>

Contact information

Type(s)

Scientific

Contact name

Prof Jack Cuzick

Contact details

Centre for Cancer Prevention
Wolfson Institute of Preventive Medicine
Charterhouse Square
London
United Kingdom
EC1M 6BQ
+44 (0)20 7882 3504
ibis@qmul.ac.uk

Type(s)

Scientific

Contact name

Miss Joanna Zahedi

Contact details

Project Manager/Data Manager
Barts CTU
Centre for Evaluation and Methods
Wolfson Institute of Population Health
Faculty of Medicine and Dentistry
Queen Mary University of London
London
United Kingdom
E1 4NS
-
j.zahedi@qmul.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2004-003992-35

ClinicalTrials.gov (NCT)

NCT00072462

Protocol serial number

N/A

Study information

Scientific Title

An international multi-centre trial of tamoxifen versus anastrozole in postmenopausal women who have had a recent hormone receptor positive, Ductal Carcinoma In Situ (DCIS)

Acronym

IBIS-II DCIS

Study objectives

Primary hypotheses:

1. To determine if anastrozole is at least as effective as tamoxifen in local control and prevention of contralateral disease in women with locally excised Estrogen Receptor (ER) or Progesterone Receptor (PgR) positive DCIS.
2. To compare side effect profiles of tamoxifen and anastrozole.

Secondary hypotheses:

1. To compare the effectiveness of tamoxifen and anastrozole according to the receptor status of the primary or recurrent cancer.
2. To examine the rate of breast cancer occurrence after cessation of tamoxifen or anastrozole.
3. To examine the effect of tamoxifen versus anastrozole on breast cancer mortality.
4. To examine the effect of tamoxifen and anastrozole on other cancers, cardiovascular disease, fracture rates, and non-breast cancer deaths.
5. To examine the tolerability and acceptability of side effects experienced by women on the study.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study has been approved by the North West MREC (Multi-centre Research Ethics Committee) and local ethics committees (LREC).

Study design

Randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

IBIS-II DCIS is a randomised double blind study investigating the use of anastrozole versus tamoxifen in women who have had a recent hormone receptor positive, locally excised DCIS lesion. There are two treatment groups:

Group A: tamoxifen 20 mg and anastrozole placebo

Group B: tamoxifen placebo and anastrozole 1 mg

Each patient will take the two tablets once a day for the next 5 years.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Tamoxifen, anastrozole

Primary outcome(s)

All new and recurrent breast cancer

Key secondary outcome(s)

1. Breast cancer mortality
2. Thromboembolic events
3. Cardiovascular events
4. Osteoporosis
5. Other relevant side effects

Completion date

31/05/2021

Eligibility

Key inclusion criteria

Current inclusion criteria as of 23/02/2012:

1. All women must be postmenopausal and between the ages of 40 and 70 years. Postmenopausal status is defined as meeting one or more of the following criteria:
 - 1.1. Over the age of 60 years
 - 1.2. Bilateral oophorectomy
 - 1.3. Aged 60 years or under with a uterus and amenorrhoea for at least 12 months
 - 1.4. Aged 60 years or under without a uterus and with Follicle-Stimulating Hormone (FSH) more than 30 IU/L
2. Women with locally excised Oestrogen Receptor (ER) positive DCIS excised within 6 months (ER or PR status must be greater than or equal to 5% positive cells)
3. A baseline bone mineral density scan within the last two years (dual-energy X-ray absorptiometry [DXA] either of hip, lumbar spine, forearm) and spinal X-ray will be required for all women
4. A fully informed signed consent form must have been obtained
5. Women who have had Lobular carcinoma in situ.
6. Women who have had Atypical hyperplasia in a benign lesion.
7. A bilateral mammogram must have been taken within the last year.
8. Women must be accessible for treatment and follow-up. Participants randomised in this trial must be treated and followed via a participating institution.

Previous inclusion criteria:

1. All women must be postmenopausal and between the ages of 40 and 70 years. Postmenopausal status is defined as meeting one or more of the following criteria:
 - 1.1. Over the age of 60 years
 - 1.2. Bilateral oophorectomy
 - 1.3. Aged 60 years or under with a uterus and amenorrhoea for at least 12 months
 - 1.4. Aged 60 years or under without a uterus and with Follicle-Stimulating Hormone (FSH) more than 30 IU/L
2. Women with locally excised Oestrogen Receptor (ER) positive DCIS diagnosed within the last 6 months in which there are tumour free margins of at least 1 mm
3. A baseline bone mineral density scan within the last two years (dual-energy X-ray absorptiometry [DXA] either of hip, lumbar spine, forearm) and spinal X-ray will be required for all women
4. A fully informed signed consent form must have been obtained

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

40 years

Upper age limit

70 years

Sex

Female

Total final enrolment

2980

Key exclusion criteria

Current exclusion criteria as of 23/02/2012:

1. Have had (or are planning to have) their breast removed (a mastectomy)
2. Have had tamoxifen or raloxifene for more than 6 months in the last 5 years
3. Have had any other cancer in the last 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
4. Are taking medication to thin the blood
5. Have had a stroke
6. Have osteoporosis and fractures of the spine (if this applies, they may be able to take part - the trial doctor will assess each person on an individual basis)
7. Have any other serious medical condition
8. Have been taking part in any other clinical trial within the last 3 months
9. Any previous breast cancer at any age
10. Life expectancy of less than 10 years or any other medical condition that would significantly interfere with the ability to accept the chemopreventive treatment

Previous exclusion criteria:

1. Have had (or are planning to have) their breast removed (a mastectomy)
2. Have had tamoxifen, raloxifene or other Selective Estrogen Receptor Modulators (SERMs) for more than 3 months in the past
3. Have had any other cancer in the last 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
4. Are taking medication to thin the blood
5. Have had a stroke
6. Have osteoporosis and fractures of the spine (if this applies, they may be able to take part - the trial doctor will assess each person on an individual basis)
7. Have any other serious medical condition
8. Have been taking part in any other clinical trial within the last 3 months

Date of first enrolment

25/05/2003

Date of final enrolment

31/01/2012

Locations**Countries of recruitment**

United Kingdom

England

Australia

Austria

Belgium

Chile

Finland

France

Germany

Hungary

India

Ireland

Italy

Malta

New Zealand

Sweden

Switzerland

Türkiye

Study participating centre
Wolfson Institute of Preventive Medicine
London
United Kingdom
EC1M 6BQ

Sponsor information

Organisation
Queen Mary University of London (UK)

ROR
<https://ror.org/026zzn846>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|--------------------------------|--------------|------------|----------------|-----------------|
| Results article | decision aid sub-study results | 01/09/2008 | | Yes | No |
| Results article | results | 27/02/2016 | | Yes | No |
| Results article | adherence results | 01/02/2018 | | Yes | No |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |